Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 18/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 18/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 15/20 | 0.64 |
| ▸ | HTR2B | P41595 | 6/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.57 |
| ▸ | HTR5A | P47898 | 1/20 | 0.57 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12269776 | 0.83 | HRH2 (0.59) | ADORA3ADORA1ADORA2AHTR2BHRH2 | |
| SCHEMBL29360010 | 0.79 | ADORA3 (0.55) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL24220640 | 0.78 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL21758645 | 0.78 | ADORA3 (0.57) | ADORA3ADORA1ADORA2AHRH2HTR5A | |
| SCHEMBL29574284 | 0.77 | HRH2 (0.53) | ADORA3ADORA1ADORA2AHTR2BHRH2 | |
| SCHEMBL21758644 | 0.77 | ADORA3 (0.55) | ADORA3ADORA1ADORA2AHRH2HTR5A | |
| SCHEMBL12269992 | 0.76 | HRH2 (0.59) | ADORA3ADORA1ADORA2AHTR2BHRH2 | |
| SCHEMBL22087932 | 0.76 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL24220484 | 0.75 | ADORA3 (0.72) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL12269874 | 0.75 | HSP90B1 (0.59) | ADORA3ADORA1ADORA2AHTR2BHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378248-B2 | A1 adenosine receptor agonists and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378248-B2 | A1 adenosine receptor agonists and methods of use thereof | ADORA1, ADORA2A, ADORA2B | ADORA3 4/4885ADORA1 1/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.